Mallinckrodt’s Uvadex Approved in Australia for Use With Therapeutic Platform

Australia’s Therapeutics Goods Administration (TGA) has approved Mallinckrodt’s Uvadex (methoxsalen) in conjunction with the Therakos Cellex photopheresis system to treat chronic graft versus host disease (cGvHD) in adults following stem cell transplantation.

The TGA also approved the combination for the palliative treatment of skin manifestations of cutaneous T-cell lymphoma that is unresponsive to other forms of treatment.

The approval is the first combined indication label and the first regulatory approval in the world for the pair to treat chronic graft versus host disease in adults.